date,title,source
Oct-22-18,Strongbridge Biopharma plc Presents Detailed Initial Results from Pivotal Phase 3 SONICS Study of RECORLEV (levoketoconazole) for the Treatment of Endogenous Cushings Syndrome at the 18th Annual Congress of the European NeuroEndocrine Association,GlobeNewswire
Oct-31-18,$181.7M deal: Strongbridge to sell rights to hormone drug to Novo Nordisk,American City Business Journals
Oct-31-18,"Strongbridge Biopharma (SBBP) Reports Q3 Loss, Misses Revenue Estimates",Zacks
Oct-31-18,Strongbridge Biopharma plc Reports Third Quarter 2018 Financial Results and Provides Corporate Update,GlobeNewswire
Oct-31-18,Strongbridge Biopharma plc Enters into Agreement for Novo Nordisk to Acquire the U.S. and Canadian Rights to MACRILEN (macimorelin),GlobeNewswire
